冠動脈ステント移植後1年以上の心房細動および安定した冠動脈疾患の患者における単一の抗血小板療法による口服抗凝固薬の比較によるオープンラベルランダム化試験
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。口服抗凝固剤 (OAC) の単独投与は,心房細動および冠動脈疾患の患者において,OACと抗血小板治療 (APT) に劣らないことが示された. 研究は早期終了のため,さらなる研究が必要でした.
科学分野
- 心臓病科
- 薬理学について
- 臨床試験
背景
- 静脈細動 (AF) と冠動脈疾患 (CAD) の患者に対する抗血栓治療のガイドラインは存在します.
- しかし,1年以上の経口抗凝固薬 (OAC) と併用抗血小板治療 (APT) を評価したランダム化比較試験 (RCT) の証拠は不足しています.
研究 の 目的
- 冠動脈ステントの設置後1年以上のAFと安定したCADの患者で,OAC単独とOACと単一のAPTの組み合わせの有効性と安全性を比較する.
- 主要な心血管不良を予防するために,OAC単独は併用療法より劣らないかどうかを判断する.
主な方法
- 将来の多中心のオープンな非劣等性試験です
- 1対1のランダム化で,OAC単独またはOACと単一のAPTを併用した.
- 主要エンドポイント:全因死亡,心筋梗塞,脳卒中,全身栓塞の複合. 二次的エンドポイント: 主要エンドポイントまたは重度の出血.
主要な成果
- 計画中の2000人の患者のうち696人が登録された後,試験は早期に終了した.
- 主要エンドポイントでは統計的に有意な差は認められなかった (15. 7% vs 13. 6%,HR 1. 16; P=0. 20 for noninferiority).
- 重度の出血事件の有意な差は認められなかった (7. 8% vs 10. 4%).
結論
- この研究は,OACとAPTの組み合わせと比較して,OAC単独の非劣等性を確立しなかった.
- 予期せぬ終止と 低パワーのため 結果は不確実です
- この患者集団の最適の抗血栓剤戦略を決定するには,より大きな研究が必要である.
関連する概念動画
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
The heart, an organ critical to survival, gets nourishment not from the blood it pumps but from a separate circulation system known as coronary circulation. This is the shortest circulation in the body and is responsible for supplying the heart with the nutrients it needs to function effectively.
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...